A newly developed breast magnetic resonance imaging (MRI) exam protocol, the first of its kind being offered in the Pacific Northwest, is now being performed at Via Radiology in north Seattle.

Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of radiopharmacies will offer Blue Earth Diagnostics’ Axumin (fluciclovine F-18) positron emission tomography (PET) imaging agent through PETNET’s national network.

2017 European Proton Therapy Congress

Magnetic resonance imaging (MRI) exams before and after space missions reveal that astronauts' brains compress and expand during spaceflight, according to a University of Michigan study.

Onxeo S.A. and the Institut Curie launched a series of studies on World Cancer Day (Feb. 4) aimed at investigating the benefits of combining radiotherapy, DNA repair inhibitors and immunotherapy. This highly innovative combination would make it possible to reverse the disease in patients suffering from drug-resistant cancers.

In humans, the part of the brain that's responsible for face recognition continues to grow into adulthood, according to a new study published in Science. The results are surprising, since brain development is largely thought to involve synaptic pruning, rather than growth. The ability to recognize faces, which is critical for everyday social interactions, improves from childhood to adulthood.

At the 2016 Radiological Society of North America (RSNA) annual meeting, GE Healthcare unveiled Freelium, a magnet technology designed to use 1 percent of liquid helium compared to conventional magnetic resonance imaging (MRI) magnets. Instead of the average 2,000 liters of precious liquid helium, Freelium is designed to use only about 20 liters.

A study published in the February issue of The Journal of Nuclear Medicine demonstrates the potential of extending peptide receptor radionuclide therapy targeting the somatostatin receptor to other types of malignancies beyond neuroendocrine tumors (NETs). The theranostic pairing of Netspot (Ga-68 DOTATATE, which is U.S. Food and Drug Administration [FDA]-approved) and Lutathera (Lu-177-DOTATATE, currently under FDA review) has already shown that it can significantly improve progression-free survival in patients with somatostatin receptor-positive NETs.

GE Advantage Workstation

At the Society of Cardiac Magnetic Resonance (SCMR) 20th Annual Scientific Sessions, GE Healthcare showcased cmr42 cardiac magnetic resonance imaging (MRI) post-processing software integrated onto its GE Advantage Workstation (AW) and AW Server platforms. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now